CHRONIX BIOMEDICAL, INC

Chronix Biomedical, Inc. is a molecular diagnostics company offering laboratory developed blood tests to doctors for cancer screening supplemental evaluations and monitoring cancer through its own certified laboratories. Chronix is privately held with headquarters in San Jose, California, and laboratories in Göttingen, Germany. Currently, Chronix Biomedical is offering 4 different tests.

stethoscope

Treatment Monitoring Test

A blood test that indicates whether a treatment is working in one to two cycles of therapy with over 90% positive predictive value.

microscope

CNI cancer evaluation
test

A blood test that reveals mutations mostly seen in patients with cancer.

heart

Second Opinion™ prostate cancer evaluation test

A blood test for men with elevated PSA that reveals the mutations mostly seen in patients with prostate cancer.

blood

Second Opinion™ breast cancer evaluation test

A blood test for patients with abnormal mammograms or lumps that reveals the mutations mostly seen in patients with breast cancer.

CHRONIX NEWS

Chronix Biomedical Study Demonstrates Its Blood Test Can Predict Response to Cancer Immunotherapy

Chronix Biomedical

Data from pilot studies using Chronix’s CNI test submitted for presentation at a high profile scientific meeting...

  • cancer diagnostics

Chronix Biomedical provides update on studies and presentations

Chronix Biomedical

Data from pilot studies using Chronix’s CNI test submitted for presentation at a high profile scientific meeting...

  • cancer diagnostics

10 Cancer Symptoms

The Times

The best way to fight cancer is to diagnose it in its early stage...

VIDEOS

Prof. Piotr Radziszewski – New generation oncological biomarkers – focusing on Chronix company

Prof. Piotr Radziszewski. New generation oncological biomarkers – focusing on Chronix company. 1.10.2016.

We present a lecture delivered at the 5th Polish women and men health debate according to Medical guidelines – kidney cancer, bladder cancer.

Paul Freiman, Chairman, Chronix – about CNI Tests

#TheTurningPointInCancerFight

Michael Oellerich, MD, Professor of George-August-University Göttingen

#TheTurningPointInCancerFight

ORDER TESTS

Go to Modern Cancer Diagnostics or Advanced Cancer Diagnostics to order our tests

EVENTS

  • laboratory

Advanced Cancer Diagnostics Showcasingat 2016 NCRI Cancer Conference 6-9 November 2016

Chronix Biomedical’s Ireland & UK distributors Advanced Cancer Diagnostics will be attending and showcasing the latest Chronix diagnostic tests: [...]

  • asco-2016

ASCO 2016

“Tumor cell-free DNA copy number instability (CNI) predicts therapeutic response to immunotherapy prior to cycle 2” , was presented [...]

PUBLICATIONS

  • Dr hab. n. med. Jakub Dobruch FEBU - liquid biopsy

Dr hab. n. med. Jakub Dobruch, FEBU – Liquid Biopsy

Dr hab. n. med. Jakub Dobruch, FEBU. Urological Review, The Polish Association of Urology bimonthly magazine. No. 5/2016

Liquid Biopsy is an example of a new kind of research that could revolutionize cancer detection and treatment of patients affected.

Prof. Piotr Radziszewski – New generation oncological biomarkers – focusing on Chronix company

Prof. Piotr Radziszewski. New generation oncological biomarkers – focusing on Chronix company. 1.10.2016.

We present a lecture delivered at the 5th Polish women and men health debate according to Medical guidelines – kidney cancer, bladder cancer.

  • first-published-results-in-breast-cancer

First published results in breast cancer

Beck J, Urnovitz HB, Mitchell WM, Schütz E. Next generation sequencing of serum circulating nucleic acids from patients with invasive ductal breast cancer reveals differences to healthy and nonmalignant controls. Mol Cancer Res 2010; 8:335-42.

Chronix has first used the NGS technology for investigation into the use in breast cancer with very promising results.

DOCTORS ABOUT OUR TESTS

“The knowledge that we have gained over the past year now suggests to us that we are able to provide to doctors and their patients the ability to diagnose at the most earliest stage the presence of cancer in their body.”
Howard Urnovitz, CEO of Chronix Biomedical for The Times
“We believe our cancer blood tests will lead to a world where no one dies unnecessarily of cancer.”
Howard Urnovitz, CEO of Chronix Biomedical